Table 1.

Patients and tumor characteristics for EBC and MBC cohorts, including populations restricted to include only relapsed patients or those with clinical follow-up greater than 5 or 6 years

CharacteristicEBC allEBC – relapsed or follow-up ≥5 yearsEBC – relapsed or follow-up ≥6 yearsMBC
Number590443319109
Age, mean (range)42 (29–50)42 (29–50)42 (29–50)39 (22–53)
Tumor size, n (%)
 <2 cm35 (5.9)23 (5.2)11 (3.5%)
 2–5 cm396 (67.1)285 (64.3)203 (63.6%)
 >5 cm159 (27)135 (30.5)105 (32.9%)
Grade, n (%)
 I74 (13)63 (14)46 (14)
 II300 (51)224 (51)162 (51)
 III115 (19)89 (20)73 (23)
 Unknown101 (17)67 (15)38 (12)
Lymph node status, n (%)
 0248 (42)166 (37.5)106 (33)
 1–3157 (27)121 (27.5)83 (26)
 >3185 (31)156 (35)130 (41)
HER2, n (%)
 Positive108 (18)90 (20.5)76 (24)
 Negative388 (66)298 (67)210 (66)
 Unknown94 (16)55 (12.5)33 (10)
ER, n (%)
 Positive552 (93.6)410 (92.6)297 (93)
 Negative37 (6.3)32 (7.2)22 (7)
 Unknown1 (0.2)1 (0.2)0 (0)
PR, n (%)
 Positive545 (92.4)405 (91.4)291 (91)
 Negative44 (7.4)37 (8.4)28 (9)
 Unknown1 (0.2)1 (0.2)0 (0)
Treatment arm, n (%)
 A186 (31.5)142 (32.0)106 (33.2)
 B216 (36.6)158 (35.7)111 (34.8)
 C188 (31.9)143 (32.3)102 (32.0)
Dominant metastatic site, n (%)
 Soft tissue79 (72.5)
 Bone17 (15.6)
 Viscera13 (11.9)
Prior systemic treatment, n (%)
 No69 (63.3)
 Yes40 (36.7)
  • NOTE: Treatment arm A: not in luteal phase at the time of trial entry, randomized to luteal phase surgery; treatment arm B: not in luteal phase at the time of trial entry, randomized to immediate, non-luteal phase surgery; and treatment arm C: in luteal phase at the time of trial entry, immediate surgery in luteal phase.

  • Abbreviation: PR, progesterone receptor.